HDAC9 and diabetes mellitus: Given that several small molecule HDAC inhibitors suitable for in vivo administration have been developed, these tools could continue to be exploited to tease out the molecular causes of kidney disease in diabetes and this new knowledge may help to pave the way to novel treatment developments in the future.